< Key Hightlight >

MARKET OUTLOOK

Triton Market Research has put forth that the Alzheimer’s disease therapeutics and diagnostics market in Latin America is likely to grow with a compound annual growth rate of 4.80% over the forecast years from 2021-2028. Brazil, Mexico, and Rest of Latin America together comprise the market in this region. 

Statistics from the Alzheimer’s Association of Mexico suggest that, the number of New Mexicans suffering from the disease reached 41,000 in 2019, which was an increase from 39,000 in 2018. This number is estimated to rise to 53,000 by 2025. Also, the elderly population in the country is expected to increase in the near future. People in this age group are more prone to disorders such as Alzheimer’s and associated dementia. This factor, in turn, is expected to drive the growth of the Mexican market in the coming years.

Further, the Government of Mexico, along with several organizations, is focusing on providing better care and management to its citizens suffering from AD. A non-profit organization based in the country, named Alzheimer México IAP, provides comprehensive care to people affected by Alzheimer’s and dementia.

In 2019, a major international research initiative was conducted in several Latin American countries, such as Mexico, Argentina, Brazil, and Colombia. It was led by the Washington University’s School of Medicine. All these factors indicate that, overall, there is a high demand for Alzheimer’s disease therapeutics and diagnostics in the region. This is benefiting the studied market growth.

COMPETITIVE OUTLOOK

F Hoffmann La Roche, GE Healthcare, Zydus Cadila, Amarantus Bioscience Holdings Inc, Sun Pharmaceuticals Industries Ltd, Pfizer Inc, Biogen Inc, Johnson & Johnson, Merck & Co Inc, and Baxter International Inc are some of the prominent names present in the Alzheimer’s disease therapeutics and diagnostics market.